Arcus Biosciences Inc (NYSE:RCUS) price closed lower on Tuesday, December 24, and dropping -0.31% below its previous close.
A look at the daily price movement shows that the last close reads $15.96, with intraday deals fluctuated between $15.5 and $15.98. The company’s 5Y monthly beta was ticking 0.89. Taking into account the 52-week price action we note that the stock hit a 52-week high of $20.31 and 52-week low of $13.52. The stock added 8.23% on its value in the past month.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Arcus Biosciences Inc, which has a market valuation of $1.46 billion, is expected to release its quarterly earnings report in January.
On average, analysts have forecast the company’s revenue for the quarter will hit 31.31M, with the likely lows of 25M and highs of 37M. The average estimate suggests sales growth for the quarter will likely rise by 1.01% when compared to those recorded in the same quarter in the last financial year. Staying with the analyst view, there is a consensus estimate of 260.53M for the company’s annual revenue in current year. Per this projection, the revenue is forecast to grow 122.68% above that which the company brought in the current year earning report.
Technical indicators in stocks provide crucial insights into market trends, guiding investors with precise entry and exit points based on price movements for informed decision-making.On the technical perspective front, indicators give RCUS a short term outlook of 50% Buy on average. Looking at the stock’s medium term indicators we note that it is averaging as a Hold, while an average of long term indicators are currently assigning the stock as 50% Sell.
Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 3 analysts have assigned RCUS a recommendation rating as follows: 0 rate it as a Hold; 3 advise Buy while 0 analyst(s) assign an Overweight rating. 0 analyst(s) have tagged the Arcus Biosciences Inc (RCUS) stock as Underweight, with 0 recommending Sell. In general, analysts have rated the stock Buy, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.
The overview shows that RCUS’s price is at present -2.87% off the SMA20 and -2.45% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 47.65, with weekly volatility standing at 5.55%. The indicator jumps to 6.05% when calculated based on the past 30 days. Arcus Biosciences Inc (NYSE:RCUS)’s beta value is holding at 0.85, while the average true range (ATR) indicator is currently reading 0.92. Considering analysts have assigned the stock a price target range of $20-$46 as the low and high respectively, we find the trailing 12-month average consensus price target to be $27. Based on this estimate, we see that current price is roughly -25.71% off the estimated low and -189.13% off the forecast high. Investors will no doubt be excited to see the share price fall to $27, which is the median consensus price, and at that level RCUS would be -69.7% from current price.
An analysis of the Arcus Biosciences Inc (NYSE:RCUS) stock in terms of its daily trading volume indicates that the 3-month average is 759.83K. However, this figure increases on the past 10-day timeline to an average of 0.81 million.
Current records show that the company has 91.50M in outstanding shares. The insiders’ percentage holdings are 46.17% of outstanding shares while the percentage share held by institutions stands at 54.49%. The stats also highlight that short interest as of 2024-11-29, stood at 8.03 million shares, which puts the short ratio at the time at 10.6. From this we can glean that short interest is 1810.00 of company’s current outstanding shares. Notably, we see that shares short in November rose slightly given the previous month’s figure stood at 6.65 million. But the -16.70% downside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.
